Journal Mobile Options
Table of Contents
Vol. 16, No. 3, 2013
Issue release date: May 2013

Stratified Cancer Screening: The Practicalities of Implementation

Dent T. · Jbilou J. · Rafi I. · Segnan N. · Törnberg S. · Chowdhury S. · Hall A. · Lyratzopoulos G. · Eeles R. · Eccles D. · Hallowell N. · Pashayan N. · Pharoah P. · Burton H.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Improving understanding of the genetic basis of disease susceptibility enables us to estimate individuals' risk of developing cancer and offer them disease prevention, including screening, stratified to reflect that risk. Little attention has so far been given to the implementation of stratified screening. This article reviews the issues that would arise in delivering such tailored approaches to prevention in practice. Results: Issues analysed include the organisational context within which implementation of stratified prevention would occur, how the offer of screening would be made, making sure consent is adequately informed, how individuals' risk would be assessed, the age at which risk estimation should occur, and the potential use of genetic data for other purposes. The review also considers how management might differ depending on individuals' risk, how their results would be communicated and their follow-up arranged, and the different issues raised by modification of an existing screening programme, such as that for breast cancer, and the establishment of a new one, for example for prostate cancer. Conclusion: Stratified screening based on genetic testing is a radically new approach to prevention. Various organisational issues would need to be considered before it could be introduced, and a number of questions require further research.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Smith A, Balazinska M, Baru C, Gomelsky M, McLennan M, Rose L, Smith B, Stewart E, Kolker E: Biology and data-intensive scientific discovery in the beginning of the 21st century. OMICS 2011;15:209-212.
  2. Pharoah PD, Antoniou AC, Easton DF, Ponder BA: Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008;358:2796-2803.
  3. Pashayan N, Duffy SW, Chowdhury S, Dent T, Burton H, Neal DE, Easton DF, Eeles R, Pharoah P: Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 2011;104:1656-1663.
  4. de Gelder R, Draisma G, Heijnsdijk EA, de Koning HJ: Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths. Br J Cancer 2011;104:1214-1220.
  5. McKee M, Suhrcke M, Nolte E, Lessof S, Figueras J, Duran A, Menabde N: Health systems, health, and wealth: a European perspective. Lancet 2009;373:349-351.
  6. Holmes MV, Harrison S, Talmud PJ, Hingorani AD, Humphries SE: Utility of genetic determinants of lipids and cardiovascular events in assessing risk. Nat Rev Cardiol 2011;8:207-221.
  7. Wright C, Burton H, Hall A, Moorthie S, Pokorska-Bocci A, Sagoo G, Sanderson S, Skinner R: Next steps in the sequence: the implications of whole genome sequencing for health in the UK. Cambridge, PHG Foundation, 2011. http://www.phgfoundation.org.
  8. General Medical Council: Consent: doctors and patients making decisions together. London, General Medical Council, 2008. http://www.gmc-uk.org/guidance/ethical_guidance/consent_guidance_index.asp.
  9. Morrow M, Waters J, Morris E: MRI for breast cancer screening, diagnosis, and treatment. Lancet 2011;378:1804-1811.
  10. Independent UK Panel on Breast Cancer Screening: The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778-1786.
  11. Petersen A, Lupton D: The New Public Health: Health and Self in the Age of Risk. London, Sage, 1996.
  12. Becker F, van El CG, Ibarreta D, Zika E, Hogarth S, Borry P, Cambon-Thomsen A, Cassiman JJ, Evers-Kiebooms G, Hodgson S, Janssens AC, Kaariainen H, Krawczak M, Kristoffersson U, Lubinski J, Patch C, Penchaszadeh VB, Read A, Rogowski W, Sequeiros J, Tranebjaerg L, van Langen IM, Wallace H, Zimmern R, Schmidtke J, Cornel MC: Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders. Eur J Hum Genet 2011;19(suppl 1):S6-S44.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50